nach oben

Erschienen in:

01.09.2012 | Original Article

The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma

verfasst von: Hiroshi Saeki, Yasushi Toh, Masaru Morita, Masahiko Sugiyama, Kazutoyo Morita, Yasuo Sakamoto, Yuji Soejima, Kazuhito Minami, Yoshihisa Sakaguchi, Yuichiro Higaki, Satoru Uehara, Takeshi Okamura, Yoshihiko Maehara

Erschienen in: Esophagus | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) have been poorly documented.

Patients and methods

We investigated 50 patients with synchronous and metachronous ESCC and HNSCC. We focused on the treatment results of 20 patients with synchronous ESCC and HNSCC who received simultaneous chemoradiotherapy (CRT).

Results

There were 34 patients (68.0 %) with stage 0–I ESCC and 40 patients (80.0 %) with stage II–IV HNSCC. A total of 13 (26.0 %) patients underwent endoscopic mucosal resection and 28 (56.0 %) underwent CRT for ESCC, and 35 (70.0 %) of the patients with HNSCC were treated with CRT. The 5-year overall survival rates of the 50 patients with synchronous and metachronous ESCC and HNSCC was 57.8 %. For the 20 patients with synchronous ESCC and HNSCC who received simultaneous CRT, the CRT was completed in 19 (95.0 %) patients. Although grade 3–4 adverse events were observed in five (25.0 %) patients, there were no therapy-related deaths. Complete responses (CRs) of both ESCC and HNSCC were observed in ten (50.0 %) patients. The 5-year overall survival rate of the 20 patients was 60.0 %. CRs of both ESCC and HNSCC were obtained in seven (58.3 %) patients by using a cisplatin/5-FU regimen (n = 12), and in the other three (37.5 %) patients by a platinum-based monotherapy regimen (n = 8).

Conclusion

The surveillance of double cancer and the use of radical treatment contributed to the favorable outcome of the patients with ESCC and HNSCC. The optimal chemotherapy regimen for simultaneous CRT remains to be determined.

Saeki H, Ohno S, Miyazaki M, Araki K, Egashira A, Kawaguchi H, et al. p53 protein accumulation in multiple oesophageal squamous cell carcinoma: relationship to risk factors. Oncology. 2002;62:175–9.PubMedCrossRef

Ito S, Ohga T, Saeki H, Nakamura T, Watanabe M, Tanaka S, et al. p53 mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. Int J Cancer. 2005;113:22–8.PubMedCrossRef

Miyazaki M, Ohno S, Futatsugi M, Saeki H, Ohga T, Watanabe M. The relation of alcohol consumption and cigarette smoking to the multiple occurrence of esophageal dysplasia and squamous cell carcinoma. Surgery. 2002;131:S7–13.PubMedCrossRef

Toh Y, Oki E, Ohgaki K, Sakamoto Y, Ito S, Egashira A, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol. 2010;15:135–44.PubMedCrossRef

Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida R, Yoshinaga K, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol. 2010;15:126–34.PubMedCrossRef

Morita M, Saeki H, Mori M, Kuwano H, Sugimachi K. Risk factors for esophageal cancer and the multiple occurrence of carcinoma in the upper aerodigestive tract. Surgery. 2002;131:S1–6.PubMedCrossRef

Tachimori Y, Watanabe H, Kato H, Ebihara S, Ono I, Nakatsuka T, et al. Treatment for synchronous and metachronous carcinoma of the head and neck and esophagus. J Surg Oncol. 1990;45:43–5.PubMedCrossRef

Morita M, Kuwano H, Ohno S, Sugimachi K, Seo Y, Tomoda H, et al. Multiple occurrence of carcinoma in the upper aerodigestive tract associated with esophageal cancer: reference to smoking, drinking and family history. Int J Cancer. 1994;58:207–10.PubMedCrossRef

Murakami S, Hashimoto T, Noguchi T, Hazamada S, Uchida Y, Suzuki M, et al. The utility of endoscopic screening for patients with esophageal or head and neck cancer. Dis Esophagus. 1999;12:186–90.PubMedCrossRef

10.

Scherubl H, von Lampe B, Faiss S, Däubler P, Bohlmann P, Plath T, et al. Screening for oesophageal neoplasia in patients with head and neck cancer. Br J Cancer. 2002;86:239–43.PubMedCrossRef

11.

Watanabe A, Hosokawa M, Taniguchi M, Sasaki S. Periodic pharyngolaryngoscopy detects early head and neck cancer and improves survival in esophageal cancer. Ann Thorac Surg. 2003;76:1699–705.PubMedCrossRef

12.

Natsugoe S, Matsumoto M, Okumura H, Ishigami S, Uenosono Y, Owaki T, et al. Multiple primary carcinomas with esophageal squamous cell cancer: clinicopathologic outcome. World J Surg. 2005;29:46–9.PubMedCrossRef

13.

Poon RT, Law SY, Chu KM, Branicki FJ, Wong J. Multiple primary cancers in esophageal squamous cell carcinoma: incidence and implications. Ann Thorac Surg. 1998;65:1529–34.PubMedCrossRef

14.

UICC International Union Against Cancer. TNM classification of Malignant Tumors, 6th edn.

15.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef

16.

Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, et al. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery. 2008;143:499–508.PubMedCrossRef

17.

Matsumoto M, Natsugoe S, Okumura H, Ishigami S, Takatori H, Nakashima H, et al. Clinicopathological and biological characteristics of esophageal squamous cell carcinoma associated with head and neck cancer. Oncology. 2004;67:98–102.PubMedCrossRef

18.

Muto M, Hironaka S, Nakane M, Boku N, Ohtsu A, Yoshida S. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc. 2002;56:517–21.PubMedCrossRef

19.

Jamieson GG, Mathew G, Ludemann R, Wayman J, Myers JC, Devitt PG. Postoperative mortality following oesophagectomy and problem in reporting its rate. Br J Surg. 2004;9:943–7.CrossRef

20.

Saeki H, Masuda T, Okada S, Ando K, Sugiyama M, Yoshinaga K, et al. Impact of perioperative peripheral blood values on postoperative complications after esophageal surgery. Surg Today. 2010;40:626–31.PubMedCrossRef

21.

Saeki H, Ishimura H, Higashi H, Kitagawa D, Tanaka J, Maruyama R, et al. Postoperative management using intensive patient-controlled epidural analgesia and early rehabilitation after an esophagectomy. Surg Today. 2009;39:476–80.PubMedCrossRef

22.

Sun K, Matsubara T, Ueda M. Surgical treatment for primary esophageal cancer developing after pharyngolaryngectomy for head and neck cancer. Surgery. 1997;122:15–9.PubMedCrossRef

23.

Wind P, Roullet MH, Quinaux D, Laccoureye O, Brasnu D, Cugnenc PH. Long-term results after esophagectomy for squamous cell carcinoma of the esophagus associated with head and neck cancer. Am J Surg. 1999;178:251–5.PubMedCrossRef

24.

Wind P, Roullet MH, Douard R, Laccoureye O, Brasnu D, Cugnenc PH. Experience in the treatment of synchronous and metachronous carcinoma of the oesophagus and the head and neck. J Surg Oncol. 2000;73:138–42.PubMedCrossRef

25.

Lo OS, Law S, Wei WI, Ng WM, Wong KH, Tong KH, et al. Esophageal cancers with synchronous or antecedent head and neck cancers: a more formidable challenge? Ann Surg Oncol. 2008;15:1750–6.PubMedCrossRef

26.

Shinoto M, Shioyama Y, Sasaki T, Nakamura K, Ohura H, Toh Y, et al. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer. Am J Clin Oncol. 2010;34:362–6.CrossRef

27.

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.PubMedCrossRef

28.

Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.PubMedCrossRef

29.

Nakajima TE, Ura T, Ito Y, Kato K, Minashi K, Nihei K, et al. A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer. Jpn J Clin Oncol. 2009;39:37–42.PubMedCrossRef

30.

Saeki H, Morita M, Nakashima Y, Sonoda H, Hashimoto K, Egashira A, et al. Neoadjuvant chemoradiotherapy for clinical Stage II–III esophageal squamous cell carcinoma. Anticancer Res. 2011;31:3073–8.PubMed

31.

Saeki H, Kawaguchi H, Kitamura K, Ohno S, Sugimachi K. Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer. J Surg Oncol. 1998;69:224–9.PubMedCrossRef

32.

Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994;12:2648–53.PubMed

33.

Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24:3693–704.PubMedCrossRef

34.

Morita M, Kumashiro R, Hisamatsu Y, Nakanishi R, Egashira A, Saeki H, et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroenterol. 2011;46:1284–91.PubMedCrossRef

35.

Yoshida R, Morita M, Ando K, Masuda T, Saeki H, Oki E, et al. Salvage esophagectomy after definitive chemoradiotherapy for synchronous double cancers of the esophagus and head-and-neck. Dis Esophagus. 2010;23:59–63.PubMedCrossRef

Titel: The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma
verfasst von: Hiroshi Saeki
Yasushi Toh
Masaru Morita
Masahiko Sugiyama
Kazutoyo Morita
Yasuo Sakamoto
Yuji Soejima
Kazuhito Minami
Yoshihisa Sakaguchi
Yuichiro Higaki
Satoru Uehara
Takeshi Okamura
Yoshihiko Maehara
Publikationsdatum: 01.09.2012
Verlag: Springer Japan
Erschienen in: Esophagus / Ausgabe 3/2012
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI: https://doi.org/10.1007/s10388-012-0334-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The treatment outcomes of synchronous and metachronous esophageal squamous cell carcinoma and head and neck squamous cell carcinoma

Abstract

Background

Patients and methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Background

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Initial experience of individualized chemoradiotherapy for superficial esophageal cancers based on the sentinel lymph node concept

A case report of benign esophageal schwannoma with FDG uptake on PET-CT and literature review of 42 cases in Japan

A case of surgical treatment for extensive corrosive stricture of esophagus and stomach after ingestion of strong hydroxide

Successful 2nd reconstruction for failed ileocolonic interposition after esophagectomy

Impact of serum biomarkers on esophageal squamous cell carcinoma

Caucasian ethnicity as a risk factor for more severe mucosal damage in gastroesophageal reflux disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin